Topic: patent expirations
Investors are running scared after a patent challenge from Amgen hit Alexion’s bestselling Soliris—but is it that big of a deal?
Amgen is working to grow sales for new meds, but in the second quarter, costly losses of exclusivity for Sensipar and Neulasta hurt the drugmaker.
For years, Roche’s blockbuster oncology troika dominated sales stateside and abroad. For Herceptin and Avastin, those landmark years could be over.
J&J's pharma unit is still on the upswing, thanks to newer meds like Stelara, but execs had to explain disappointing numbers from two blockbusters.
U.S. Rep. Elijah Cummings is leading an effort to determine if Gilead's largesse is tied to its efforts to protect Truvada's patents.
Plaintiffs are piling into court claiming AbbVie quashed Humira competition with a "patent thicket" and an illegal “pay-for-delay" deal.
Avastin is Roche’s third cancer blockbuster expected to come up against 2019 biosimilar competition in the U.S. Roche has billions at stake as biosims creep to the critical market.